[{"id":"ddddb0c6-f7f5-4ac6-a188-f261d868f474","acronym":"","url":"https://clinicaltrials.gov/study/NCT05061251","created_at":"2021-09-29T11:53:53.576Z","updated_at":"2025-02-25T17:25:16.827Z","phase":"Phase 1","brief_title":"Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma","source_id_and_acronym":"NCT05061251","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e orludodstat (BAY2402234)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-01-11"}]